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Abstract
Donepezil has been shown to be well tolerated and to
improve cognition and global function in patients with
mild to moderately severe Alzheimer’s disease (AD). The
current trial was undertaken to investigate further the effi-
cacy and safety of donepezil, in a multinational setting, in
patients with mild to moderately severe AD. This 30-week,
placebo-controlled, parallel-group study consisted of a
24-week, double-blind treatment phase followed by a 6-
week, single-blind, placebo washout. Eight hundred and
eighteen patients with mild to moderately severe AD were
randomly allocated to treatment with single, daily doses
of 5 or 10 mg donepezil, or placebo. The two primary effi-
cacy measures were: a cognitive performance test, the
Alzheimer’s Disease Assessment Scale-cognitive sub-
scale (ADAS-cog) and a global evaluation, the Clinician’s
Interview-Based Impression of Change with caregiver in-
put (CIBIC plus). Secondary outcome measures included
the Sum of the Boxes of the Clinical Dementia Rating
Scale (CDR-SB), a modified Interview for Deterioration in
Daily living activities in Dementia (IDDD) and a patient-
rated quality of life assessment. Statistically significant
improvements in cognitive and global function were ob-
served, as evaluated by ADAS-cog and CIBIC plus, respec-
tively, in both the 5 and 10 mg/day donepezil groups,
compared with placebo. Treatment-associated changes
were also observed in functional skills, as shown by
improved scores on the CDR-SB and the complex-tasks
component of the IDDD. A dose–response effect was evi-
dent, with the 10 mg/day donepezil group demonstrating
greater benefits in all outcome measures than the 5 mg/
day group. Donepezil was well tolerated by this patient
population and did not produce any clinically significant
laboratory test abnormalities. The results of this study
confirm that donepezil is effective and well tolerated in
treating the symptoms of mild to moderately severe AD.
Introduction
Alzheimer’s disease (AD) is a progressive disease, char-
acterised by disorders of cognitive function, deficits in
activities of daily living and the presence of psychiatric
symptoms and behavioral disturbances. It is primarily a
condition of elderly people, affecting 3% of 70-year-olds,
rising to 10% in people over 80 [1]. The pathogenesis of
AD is not understood. There is, however, widespread loss
of cholinergic innervation to the cerebral cortex, which
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forms the basis for memory impairment, a hallmark of the
disease [2]. Theoretically, increasing the levels of brain
acetylcholine may improve clinical symptoms in AD.
Most successful therapeutic strategies have focused on
blocking the breakdown of acetylcholine by inhibiting its
enzymatic hydrolysis.
Donepezil hydrochloride (Aricept®)4 is a potent and spe-
cific inhibitor of acetylcholinesterase with minimal effects
on butyrylcholinesterase [3] and, as a piperidine-based mol-
ecule, is chemically distinct from other cholinesterase in-
hibitors. It has a long duration of action, with a half-life of
approximately 70 h [4–6], which allows once-daily admin-
istration. Preclinical [7] and clinical studies in Japan [8]
and the USA [9] have shown that donepezil is devoid of
unexpected toxicity, particularly the hepatotoxicity charac-
teristic of acridine-based cholinesterase inhibitors.
Phase II and Phase III [10, 11] double-blind, placebo-
controlled clinical trials conducted in the USA have
shown that donepezil significantly improves cognitive
and global function, with these benefits being maintained
during open-label, long-term donepezil administration
[12]. Donepezil was studied in a population where 95% of
patients had prior medical or co-morbid conditions, and
was shown to be well tolerated, producing no clinically
significant changes in metabolic, cardiovascular, hepatic
or renal function. In addition, no clinically significant
drug-drug interactions were observed, even though over
80% of the patients in these trials were taking one or more
concomitant medications. Importantly, the cytochrome
P450 isoenzyme inhibitors cimetidine [13] and ketocona-
zole [14] produce no clinically significant changes in the
pharmacokinetics of donepezil, suggesting that dose mod-
ification is not necessary when donepezil is co-adminis-
tered with such compounds.
The objectives of the current study were to evaluate
further the safety and efficacy of once-daily administra-
tion of donepezil at doses of 5 and 10 mg, versus placebo,
in a large, multinational cohort of patients with mild to
moderately severe AD.
Materials and Methods
Patient Population
Men and women, 650 years of age, with probable AD were
recruited at 82 sites in Australia, Belgium, Canada, France, Germany,
Ireland, New Zealand, South Africa and the UK. For the diagnosis of
AD, patients satisfied both the criteria defined by the DSM-III-R for
primary degenerative dementia of the Alzheimer type [15] and by the
guidelines of the National Institute of Neurological and Communica-
4 Aricept® is a registered trademark of Eisai Co. Ltd., Tokyo, Japan.
tive Disorders and Stroke and Alzheimer’s Disease and Related Dis-
orders Association (NINCDS-ADRDA) for probable AD [16].
Patients were required to have mild to moderately severe AD, at
screening and baseline, as defined by Mini-Mental State Examina-
tion [17] scores between 10 and 26 inclusive, and Clinical Dementia
Rating (CDR) [18] scores of 1 (mild) or 2 (moderate). All patients had
a computerised tomography or magnetic resonance imaging scan
within the previous 6 months, and patients with structural lesions or
significant vascular changes were excluded. Women were required to
be 2 years post-menopausal or surgically sterile. In addition, patients
had to be generally healthy, with vision and hearing sufficient for
compliance with the testing procedures. Patients with other neuro-
logical or psychiatric disorders, asthma, significant uncontrolled gas-
trointestinal, renal, hepatic, endocrine or oncological disorders, or
who were taking prohibited study medications, were excluded.
The study was conducted in accordance with the principles stated
in the revised Declaration of Helsinki (1989) and the European Com-
munity GCP Guidelines (1990). All centres had local ethics commit-
tee approval. Prior to screening, the nature and purpose of the inves-
tigation was explained to the patient and caregiver, and written,
informed consent was obtained from both.
Study Design
This was a 30-week, randomised, multinational, multicentre, pla-
cebo-controlled, parallel-group study with a 24-week, double-blind
treatment phase followed by a 6-week, single-blind, placebo washout.
Patients were screened within 2 weeks of entry and randomly
assigned to receive 5 or 10 mg/day donepezil, or placebo. Study med-
ication was administered orally, once-daily, in the evening. A blinded
schedule was used for the 10 mg/day donepezil group, where patients
initially received 5 mg/day for the first 7 days, then 10 mg/day for the
remainder of the study. Efficacy and safety evaluations were con-
ducted at baseline and at Weeks 6, 12, 18, 24 and 30.
Outcome Measures
The Alzheimer’s Disease Assessment Scale-cognitive subscale
(ADAS-cog) [19], and a Clinician’s Interview-Based Impression of
Change with caregiver input (CIBIC plus) [20], were the two primary
outcome measures used, reflecting cognition and global function,
respectively.
The secondary efficacy variables used were the Sum of the Boxes
of the Clinical Dementia Rating scale (CDR-SB) which sums the rat-
ings from six domains (‘boxes’) of the CDR to provide a consensus-
based, global clinical measure [21], a modified Interview for Deterio-
ration in Daily living activities in Dementia (IDDD) [22] and a
patient-rated quality of life (QoL) assessment [23]. Descriptions of
ADAS-cog, CIBIC plus, CDR-SB and QoL assessment tools have
been reported previously [10, 11].
The IDDD was designed originally as a severity instrument for
quantifying impairment in activities of daily living of dementia
patients. It consists of 33 items and the severity of impairment is
rated on a 7-point scale, where 1–2 = no or slight impairment, 3–4 =
mild impairment, 5–6 = moderate impairment and 7 = severe
impairment, giving a total score range of 33–231 points. The IDDD
provides a self care tasks rating (16 items) and complex tasks rating
(17 items). Both initiation of tasks and their performance by the
patient are quantified during a structured interview of the caregiver.
At baseline, severity of disability was scored for each item of the
IDDD. To assess change at subsequent visits, the severity scale was
modified to measure change from baseline, where the evaluator rated
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improvement, no change or deterioration in comparison to the base-
line performance level. In assessment of change, a 7-point Likert-type
scale was used, where 1 = marked improvement from baseline, 4 = no
change from baseline and 7 = marked deterioration from baseline.
Hence, a patient exhibiting no change in complex task functioning,
for example, would receive a total score of 68 (17 ! 4) on the IDDD
complex tasks. Thus, it follows that a score below 68 would represent
improvement and a score above 68 would denote deterioration. This
trial represents the first use of this modification of the IDDD scale.
Unlike the ADAS-cog and CIBIC plus assessment tools, which are
widely accepted in research settings, there are no instruments to mea-
sure change in the patients’ ability to perform both complex and ba-
sic daily tasks that are in common use in clinical trials for AD.
Safety Measures
Adverse events were monitored at each visit by questioning both
the patient and the caregiver, as well as through direct observation.
All adverse events, whether reported or observed, were recorded,
together with the time and date of onset and cessation, severity of
condition and whether, in the opinion of the investigator, the event
was related to donepezil treatment. Serious adverse events (SAE)
included fatal or life-threatening situations, permanently disabling
conditions or incidents that required or prolonged hospitalisation.
Blood pressure and pulse were measured at all clinic visits, with
temperature and respiration also measured at baseline and Week 30.
A standard 12-lead ECG was performed at the start and end of the
double-blind treatment. In addition, clinical laboratory assessments
including haematology, clinical chemistry and urinalysis were con-
ducted at each clinic visit.
Statistical Assessments
An original sample size of 150 patients/treatment group was esti-
mated, based on the results obtained from an earlier Phase II study of
donepezil and from published results from US tacrine trials. The
sample size had 80% power to detect a difference of 0.27 points in
mean CIBIC plus scores for each donepezil treatment group when
compared to placebo, at a 0.05 significance level. The patient com-
pletion rate was estimated to be 80%. During the study, a blinded
examination of the ADAS-cog test data indicated a larger variance in
the multinational data than projected from the US data. This was not
unexpected given the multinational nature of this patient cohort.
However, to ensure a valid representation of the patient cohort it was
thus necessary that the sample size be increased to 250 patients per
treatment group. The final sample size of 818 was a result of addi-
tional patients already in screening at the time of termination of
recruitment.
Three populations were used in the analyses of efficacy: fully eval-
uable, retrieved drop-out and intention-to-treat (ITT). The ITT pop-
ulation was analysed on both observed cases and traditional last
observation carried forward (LOCF; endpoint, as outlined by the US
FDA [24]). As specified a priori, the primary population was the ITT,
and the primary endpoint was the Week 24 LOCF. Since the results
of all analyses were similar, only the primary analysis is presented in
this report.
For the continuous variables (ADAS-cog, modified IDDD, CDR-
SB and QoL), an analysis of covariance (ANCOVA) model was used
to compare treatment groups. The models for efficacy contained fac-
tors for baseline score, treatment effect and centre effect. The
assumptions of the covariance were tested before using the reduced
model. Fisher’s least significant difference procedure was used to
control for multiple comparisons to placebo.
Table 1. Patient demographics
Placebo Donepezil
5 mg/day 10 mg/day
274 271 273
Age, years
Mean B SE 71B0.5 72B0.5 72B0.5
Range 50U90 51U91 53U93
Gender
Male 123 (45) 107 (39) 118 (43)
Female 151 (55) 164 (61) 155 (57)
Race
Caucasian 272 (99) 270 (100) 271 (99)
Other 2 (1) 1 (!1) 2 (1)
Weight, kg
Mean B SE 66B0.8 65B0.8 66B0.7
Range 37U107 38U108 38U99
Screening MMSE
Mean B SE 20B0.3 20B0.3 20B0.2
Range 10U26 10U26 9U26
Screening CDR
0.5 0 2 (1) 2 (1)
1.0 230 (84) 222 (82) 236 (86)
2.0 44 (16) 47 (17) 35 (13)
Figures in parentheses are percentages. MMSE = Mini-Mental State Exam-
ination.
For the categorical efficacy variable (CIBIC plus), the Cochran-
Mantel-Haenszel test was employed, with RIDITS as the score
option and stratified for centre [25, 26].
Demographic variables of age, weight and height were investi-
gated utilising ANOVA models with factors for treatment and centre.
Sex was assessed by the Cochran-Mantel-Haenszel test with centres
as strata.
Within-group changes in vital signs were analysed using paired
t-tests. Between-group differences were investigated by ANCOVA
models. As in previous studies, the analysis of adverse events was
restricted to signs and symptoms that either began, or became more
severe, after administration of the first dose of study medication.
Events were coded using a modified COSTART dictionary [27], and
the assessment of relationship to treatment for all adverse events was
conducted blind to treatment assignment. The incidence of adverse
events and laboratory test abnormalities were compared between
treatment groups using Fisher’s exact test.
All statistical analyses were undertaken by an independent clini-
cal research organization using SAS version 6 or higher (SAS Insti-
tute, Cary, N.C., USA). All hypothesis tests were two-sided and sta-
tistical significance was achieved if p ^ 0.05.
Results
Description of the Sample
A total of 818 patients were randomised to treatment.
The treatment groups were comparable with respect to all
the demographic variables examined (table 1). The com-
240 Dement Geriatr Cogn Disord 1999;10:237–244 Burns/Rossor/Hecker/Gauthier/Petit/
Möller/Rogers/Friedhoff
Fig. 1. LS mean (BSE) change from base-
line in ADAS-cog scores for 5 and 10 mg/day
donepezil and placebo groups.
Fig. 2. Mean (BSE) CIBIC plus scores for
5 and 10 mg/day donepezil and placebo
groups; p values were calculated using the
Cochran-Mantel-Haenszel test.
Fig. 3. LS mean (BSE) change from base-
line in CDR-SB scores for 5 and 10 mg/day
donepezil and placebo groups.
IDDD-total score
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Fig. 4. LS mean (BSE) change from base-
line in IDDD-complex tasks scores for 5 and
10 mg/day donepezil and placebo groups.
pletion rates for this study were high at 78, 74 and 80% for
the 5 and 10 mg/day donepezil and placebo groups,
respectively.
Primary Outcome Measures
ADAS-cog. There was a statistically significant im-
provement in ADAS-cog scores for the two donepezil-
treated groups compared with placebo. This was observed
at Week 6 and maintained throughout the active treat-
ment phase (fig. 1). At endpoint, the donepezil versus pla-
cebo differences in least-squares (LS) means for change
from baseline ADAS-cog scores were 1.5 and 2.9 points
for the 5 and 10 mg/day donepezil groups, respectively.
CIBIC plus. Statistically significantly greater numbers
of donepezil-treated patients were judged clinically im-
proved, by comparison with placebo. This beneficial drug
treatment effect was observed from Week 6 and was main-
tained at all subsequent visits (fig. 2) and at endpoint. Don-
epezil increased the percentage of patients rated as im-
proved (CIBIC plus scores ^3 at endpoint): 21 and 25%
for the 5 and 10 mg/day donepezil-treated groups, respec-
tively, compared with 14% for the placebo group. In addi-
tion, donepezil reduced the percentage of treatment fail-
ures (CIBIC plus scores 65 at endpoint: 43 and 37% for
the 5 and 10 mg/day donepezil-treated groups, respective-
ly, compared with 51% for the placebo group.
Secondary Outcome Measures
CDR-SB. Statistically significant improvements in LS
mean change CDR-SB scores were observed for both do-
nepezil-treated groups, versus placebo, at Weeks 12, 18,
24 and endpoint (p ! 0.05; fig. 3). At endpoint, the mean
drug–placebo differences for the 5 and 10 mg/day donepe-
zil groups were 0.3 and 0.4, respectively.
Table 2. IDDD baseline severity scores – ITT population
Placebo Donepezil
5 mg/day 10 mg/day
Total baseline severity
(possible range 33–231)
69.84B1.68 67.78B1.61 69.85B1.71
Mean severity per item 2.10 2.04 2.09
IDDD-self care
Total baseline severity
(possible range 16–112)
24.31B0.72 23.14B0.61 23.72B0.66
Mean severity per item 1.52 1.45 1.48
IDDD-complex tasks
Total baseline severity
(possible range 17–119)
45.53B1.17 44.64B1.13 46.12B1.21
Mean severity per item 2.68 2.63 2.71
Means B SE. The severity scale per item: 1–2 = no or slight impairment;
3–4 = mild impairment; 5–6 = moderate impairment; 7 = severe impairment.
IDDD. The mean total baseline IDDD severity scores
were low (F70 out of a total of 231), with a mean score of
2.1 points per item, indicating that patients entering this
study had very mild functional impairment on this scale
(table 2). The mean IDDD-self care and IDDD-complex
task scores per item at baseline were 1.5 and 2.7, respec-
tively, demonstrating that patients had little or no impair-
ment of self-care abilities and only mild impairment in
the execution of complex tasks.
From Week 6, through the active treatment phase,
IDDD-complex task scores for both the 5 and 10 mg/day
donepezil groups were improved when compared with
placebo, with statistical significance for the 10 mg/day
donepezil dose at all assessments (fig. 4). As IDDD-self
care scores in this patient population were not impaired at
Patients randomised
Total patients with
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Table 3. Patient disposition
Placebo Donepezil
5 mg/day 10 mg/day
All
donepezil
treatments
274 271 273 544
Patients discontinued 55 (20) 60 (22) 72 (26) 132 (24)
Withdrawn due to:
Adverse events1, 2
Body as a whole
Cardiovascular
Digestive
Nervous
27 (10)
6 (2)
3 (1)
2 (!1)
14 (5)
24 (9)
4 (1)
1 (!1)
4 (1)
13 (5)
50 (18)
12 (4)
5 (2)
27 (10)
21 (10)
74 (14)
16 (3)
6 (1)
31 (6)
34 (6)
Intercurrent illness 3 (1) 0 0 0
Request of patient
or investigator
6 (2) 12 (4) 6 (2) 18 (3)
Non-compliance 2 (1) 3 (1) 2 (1) 5 (1)
Protocol violation 13 (5) 13 (5) 8 (3) 21 (4)
Other 4 (1) 8 (3) 6 (2) 14 (3)
Figures in parentheses are percentages.
1 There may be more than one adverse event that led to withdrawal.
2 Adverse events and symptoms were not necessarily treatment related or
treatment emergent.
Table 4. Adverse events experienced by at least 5% of all donepezil
patients
Placebo Donepezil
5 mg/day 10 mg/day
All
donepezil
treatments
any adverse events 207 (76) 213 (79) 234 (86) 447 (82)
Digestive system1
Nausea1
Diarrhoea1
Vomiting1
Anorexia
65 (24)
7%
4%
4%
1%
70 (26)
7%
10%
4%
4%
127 (47)
24%
16%
16%
8%
197 (36)
16%
13%
10%
6%
Nervous system1
Dizziness
Confusion
Insomnia
80 (29)
5%
6%
4%
98 (36)
5%
7%
7%
109 (40)
9%
6%
8%
207 (38)
7%
7%
8%
Total patients with SAE 25 (9) 19 (7) 29 (11) 73 (9)
Figures in parentheses are percentages.
1 Donepezil groups significantly differed from placebo, p ^ 0.05 employing
Fisher’s exact test.
baseline, no improvements could be measured during the
study.
QoL. The mean change from baseline at each evalua-
tion of this patient-rated measure was associated with a
large standard error, indicating the high variability of
responses from patients. As such, no clear trends among
the treatment groups were evident during the active phase
of this trial and no overall treatment effects were observed
at any assessment visit. This reflects the difficulties inher-
ent in using patient-rated instruments in populations with
cognitive impairment.
Treatment Washout. Following the 6-week, single-
blind, placebo washout phase, patient scores for efficacy
measures (ADAS-cog, CIBIC plus, CDR-SB and IDDD)
reverted to levels similar to placebo, indicating that the
beneficial effects of donepezil were lost when treatment
was discontinued (figs. 1–4).
Safety Measures
Donepezil was well tolerated: 76% of donepezil-treated
patients, compared with 80% of the placebo group, com-
pleted the study (table 3). A low incidence of patients with-
drew due to adverse events: only 9 and 18% for the 5 and
10 mg/day donepezil groups, respectively, as compared
with 10% in the placebo group (table 3), and not all events
were treatment-emergent or treatment-relevant. The most
frequently experienced adverse events were digestive sys-
tem related (nausea, vomiting and diarrhoea; tables 3
and 4), which are predictable effects of cholinergic drugs.
The percentage of patients experiencing cholinergic-in-
duced side-effects was higher in the 10 mg/day donepezil
group and was likely to be due to the rapid increase to the
10 mg/day dose after only 1 week on 5 mg/day [28, 29].
Overall, the proportion of patients with at least one
reported adverse event within the donepezil groups was
only slightly higher than in the placebo group (table 4).
The majority of these events were mild and transient in
nature, typically lasting 1–2 days and resolving during
continued donepezil use, without dosage adjustment.
Most adverse events, other than those clearly cholinergic
in nature, were judged by the investigators not to be relat-
ed to donepezil treatment.
Of the 818 patients enrolled in the study, 73 (9%) expe-
rienced at least one SAE either during the study or within
1 month of study termination; the incidence of SAEs was
similar for all treatment groups and unrelated to study
medication (table 4). Five patients (two receiving placebo,
one receiving 5 mg/day donepezil and two receiving 10
mg/day donepezil) died during the study or within 1
month of stopping medication. All 5 deaths were deter-
mined to be unrelated to donepezil treatment.
No clinically significant abnormal test values, for any
laboratory parameter, were observed at a greater frequen-
cy in the donepezil-treated patients as compared with the
placebo group. In particular, donepezil was not associated
with evidence of hepatotoxicity.
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Discussion
The results of this Phase III, multinational, clinical
trial confirm previously published findings that the daily
doses of both 5 and 10 mg donepezil significantly improve
cognitive and global functioning in patients with mild to
moderately severe AD, with an effect size similar to those
reported in the US 30-week, Phase III trial of donepezil.
Hence, these improvements in cognitive and global func-
tion were consistent and independent of the populations
studied (US versus multinational).
In addition to cognition and global function, this study
assessed the effects of donepezil treatment on activities of
daily living (IDDD-complex tasks and IDDD-self care).
These subscores measure aspects of early- and late-stage
AD progression, respectively [30]. In the early stages of
the disease, patients primarily experience difficulty with
relatively complex activities, such as handling finances or
preparing meals (complex tasks). It is not until later in the
disease course that basic activities of daily living (self
care) become affected, e.g. dressing, bathing, etc. Consis-
tent with this premise, the mildly to moderately demented
patient population in this study had well-preserved basic
skills, but mildly impaired complex task performance.
Thus, as might be expected, donepezil administration
did not improve the well-preserved, self care task perfor-
mance scores of this patient population. By contrast,
improvements relative to placebo, in complex task perfor-
mance scores, were observed for both the 5 and 10 mg/day
donepezil groups, at all treatment visits, with statistically
significant differences obtained for the 10 mg/day done-
pezil group versus placebo.
Consistent with earlier trials, this study confirms
that the 5 mg/day dose of donepezil is clinically effective,
as assessed by the ADAS-cog and CIBIC plus. In addi-
tion, and in agreement with previous study findings, a
dose–response effect is evident, with patients receiving
10 mg/day donepezil demonstrating greater sustained
benefits.
Both doses of donepezil were well tolerated. The higher
incidence of cholinergic adverse events experienced in the
10 mg/day donepezil group, as compared with the 5 mg/
day donepezil and placebo groups, has been shown in a
separate study to be a direct result of the rapid dose
increase used (5 mg/day for the first 7 days, then 10 mg/
day thereafter). When the patients’ dosage had been
increased to 10 mg/day donepezil after 4–6 weeks of treat-
ment at 5 mg/day, the adverse event profile for 10 mg/day
donepezil was similar to that of both the 5 mg/day done-
pezil- and placebo-treated groups. However, despite the
rapid dose increase used in this study, the discontinuation
rates related to adverse events are substantially lower than
those reported for other cholinesterase inhibitors, such as
tacrine [31] and physostigmine. Common side-effects ex-
perienced in this study (65%) included nausea, vomiting,
diarrhoea, anorexia, dizziness, confusion and insomnia,
and are consistent with adverse events reported in pre-
vious studies.
Results of this multinational trial confirm previous
findings that donepezil is well tolerated and efficacious in
treating the symptoms of cognitive loss and in improving
global functioning in patients with mild to moderately
severe AD. The improvement in IDDD-complex tasks also
indicates that the benefits of donepezil may translate into
an effect on complex activities of daily living. Thus, despite
variations in local diagnostic and treatment practices, this
multinational study demonstrates that donepezil therapy is
an effective and well tolerated symptomatic treatment for
patients with mild to moderately severe AD.
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